Showing results (891-900 of 1,490) with videos related to

Sort By:
Pageof 149
European Journal of Cancer (Oxford, England : 1990)|March 28, 1998
Loss of heterozygosity for chromosome 1p in familial neuroblastomaG P Tonini, C Lo Cunsolo, R Cusano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 4, 2016
Does robot-assisted gait training improve ambulation in highly disabled multiple sclerosis people? A pilot randomized control trialAlessandra Pompa, Giovanni Morone, Marco Iosa, et al.
International Journal of Surgery (London, England)|November 8, 2016
Impact of octogenarians on surgical outcome in colorectal cancerBasilio Pirrera, Samuele Vaccari, Dajana Cuicchi, et al.
Anticancer Research|May 7, 2017
EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung CancerFilippo DE Marinis, Paolo Bidoli, Andrea Luciani, et al.
Neurobiology of Disease|October 5, 2014
Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortexTiziana Rubino, Pamela Prini, Fabiana Piscitelli, et al.
Food Chemistry|December 23, 2025
Bacterial-driven lipid remodeling in avocado fermentation via hydroxylation and oxidation routesAli Zein Alabiden Tlais, Ilario Losito, Pasquale Filannino, et al.
Plos Biology|July 29, 2025
Behavioral inflexibility through overtraining is mediated by reduced mGluR1/5 signaling capacity in the dorsolateral striatumVincent Paget-Blanc, Anna Cavaccini, Alessandra Longaretti, et al.
Helvetica Paediatrica Acta|February 1, 1981
Immunological evaluation of 22 patients with acute lymphoblastic leukemia off-therapy. A longitudinal follow-upM Pasino, C R Vadalà, B De Bernardi, et al.
Oncology|November 13, 2004
Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapyDaniele Santini, Bruno Vincenzi, Giuseppe Perrone, et al.
BMJ Open|February 9, 2020
Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trialBruno Vincenzi, Mike Trower, Ajay Duggal, et al.
Pageof 149